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OBJECTIVE — Toinvestigatetheeffectofbenfotiamineonurinaryalbuminexcretion(UAE)
and the tubular damage marker kidney injury molecule-1 (KIM-1) in patients with type 2
diabetes and nephropathy.
RESEARCH DESIGN AND METHODS — Patients with type 2 diabetes and UAE equiv-
alent to 15–300 mg/24 h, despite ACE inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs),
were randomly assigned to 12 weeks of benfotiamine (900 mg/day) (n  39) or placebo (n  43).
RESULTS — Compared with placebo, benfotiamine treatment resulted in signiﬁcant im-
provementofthiaminestatus(P0.001).Benfotiaminetreatmentdidnotsigniﬁcantlydecrease
24-h UAE or 24-h KIM-1 excretion.
CONCLUSIONS — In patients with type 2 diabetes and nephropathy, high-dose benfo-
tiamine treatment for 12 weeks in addition to ACE-Is or ARBs did not reduce UAE or KIM-1
excretion, despite improvement of thiamine status.
Diabetes Care 33:1598–1601, 2010
T
he pathophysiology of diabetic ne-
phropathy includes albuminuria as
a consequence of glomerular endo-
thelial damage and further progression
due to tubulointerstitial inﬂammation
and ﬁbrosis (1,2). Despite protective
treatment with ACE inhibitors (ACE-Is)
and angiotensin receptor blockers
(ARBs), many patients progress to end-
stage renal disease (3).
Thiamine and benfotiamine have
beenproposedasprotectiveagentsfordi-
abetes complications (4,5). Benfotiamine
is a lipophilic thiamine derivative with
highbioavailability(6).Inanimalstudies,
bothcompoundshadbeneﬁcialeffectson
microvascular complications, including
diabetic nephropathy (5,7).
We investigated whether benfo-
tiamine results in reduction in urinary
albumin excretion (UAE) or tubulointer-
stitial damage markers in patients with
type 2 diabetes and increased UAE de-
spite ACE-Is or ARBs.
RESEARCH DESIGN AND
METHODS— Participants were re-
cruited at the Isala Clinics (Zwolle, the
Netherlands).Inclusioncriteriaweretype
2 diabetes, age 40–75 years, active dia-
beticnephropathy(UAE15–300mg/24h
or equivalent albumin-to-creatinine ratio
[males 1.25–25, females 1.75–35 mg/
mmol]intwoofthreesampleswithin2–6
weeks)despiteACE-Isand/orARBsinun-
changed dose for at least 3 months, gly-
cated hemoglobin (A1C) 8.5%, and an
estimated glomerular ﬁltration rate of
30 ml/min. Exclusion criteria were par-
ticipation in another study, renal impair-
ment by causes other than diabetes,
elevated liver enzymes, hyper- or hypo-
thyroidism, blood pressure 160/90
mmHg, neoplasm, severe general dis-
eases, drug abuse, pregnancy, lactation,
active menses, hypersensitivity to benfo-
tiamine,useofvitaminB–containingsup-
plements, changes in concomitant
medication during the previous 3
months, and use of nonsteroidal anti-
inﬂammatory drugs 3 times per week.
In total, 2,711 patients were screened. El-
igiblepatientswereincludedafterwritten
informed consent was received. The trial
was approved by the medical ethics
committee.
Patientswererandomizedtooralben-
fotiamine300mgthreetimesdailyorpla-
cebo for 12 weeks. Study medication was
preparedbyWo ¨rwagPharma(Bo ¨blingen,
Germany). Participants were evaluated at
baseline and after 6 and 12 weeks. Each
visit, 24-h urine, spot morning urine, and
blood samples were collected. Noncom-
pliance was considered if 80% of the
study medication had been taken.
Thiamine concentration was mea-
suredinwholebloodandplasmabyhigh-
performance liquid chromatography (8).
Erythrocyte transketolase activity was
measured in erythrocytes (9). Urinary al-
bumin was measured by immunoneph-
elometry (Behring Nephelometer;
Mannheim,Germany),threshold1.8–2.3
mg/l, intra- and interassay coefﬁcients of
variation(CV)2.2and2.6%,respectively.
Urinary kidney injury molecule-1
(KIM-1) was measured by ELISA, thresh-
old 0.12 ng/ml, intra- and interassay CV
7.9and14.4%,respectively(10).Neutro-
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1-microglobulin were measured by
ELISA and cystatin C by immunoassay
(Gentian; Moss, Norway). Other labora-
tory measurements were performed ac-
cording to standard procedures.
Statistical analyses
Variables with normal distribution are
presented as means  SD. Variables with
skewed distribution were log-trans-
formed before analysis and are presented
as median (interquartile range). Changes
were analyzed by ANOVA for repeated
measurements. P values for change over
time are presented. Results were consid-
ered statistically signiﬁcant with P 
0.05.
Totestwhetherbenfotiaminereduces
24-h UAE or 24-h KIM-1 excretion, 38
evaluable patients per group were re-
quired to detect an effect of size 0.65
(power 80%, 0.05, one-sided test).
To compensate for drop-out, we enrolled
43patientspergroup.One-sidedPvalues
were calculated for primary outcome
measuresandtwo-sidedPvaluesforother
outcomes. Statistics were done by SPSS,
version 16.0 (Chicago, IL). Intention-to-
treat analysis and per-protocol analyses
were planned. In cases of drop-out, data
were not replaced.
RESULTS— Baseline characteristics
and results at 6 and 12 weeks are shown
in Table 1. In the benfotiamine group,
two patients did not complete the study
because of newly diagnosed malignancy
and two others withdrew informed con-
sent (dizziness and urticaria). In patients
receivingbenfotiamine,parametersofthi-
amine status improved signiﬁcantly. Ben-
fotiamine treatment had no signiﬁcant
effect on primary or secondary outcome
parameters. Change in UAE between
baseline and 12 weeks was 18 mg/24 h
in the benfotiamine group and 1 mg/24
hintheplacebogroup.Forindividualdif-
ferences, respective changes were 9
(53 to 34)mg/24 h and 7 mg/24
h(56 to 65). With respect to clinical
characteristics, benfotiamine resulted in a
borderline signiﬁcant increase in plasma
creatinine, but this was not accompanied
by changes in creatinine clearance or cys-
tatin C.
During the study, two patients were
noncompliant (one per group) and two
protocol violations occurred in the pla-
cebo group (ACE-I stopped), resulting in
38 patients in the benfotiamine and 40 in
the placebo group for per-protocol anal-
yses, of which results (data not shown)
were not materially different from pre-
sented analyses.
CONCLUSIONS— We found that
12-weektreatmentwithhigh-dosebenfo-
tiamine did not result in decreases in 24-
h–UAE or 24-h–KIM-1 excretion despite
signiﬁcant improvement of thiamine
status.
Our ﬁndings differ from those of a
pilot study of 40 patients with type 2 di-
abetes in which 12 weeks of 300 mg/day
of thiamine resulted in a signiﬁcant de-
crease in UAE by 17.7 mg/24 h (11). In
that study, baseline UAE was 44 mg/24 h
(33–121) in the thiamine and 51 mg/24 h
(32–122) in the placebo group, which is
approximately 2 times lower than in our
study, despite 100% of ACE-I and ARB
treatment in our study versus 50% in
the pilot study (12). Thus, thiamine de-
rivatives may provide protective effects in
earlier diabetic nephropathy stages,
which is in line with an animal study in
which development of albuminuria after
induction of diabetes was inhibited by
thiamine and benfotiamine (5). Further-
more,weinvestigatedCaucasianpatients,
and the other study was of Pakistani pa-
tients. Thus, differences in diet, baseline
prevalence of thiamine deﬁciency, or ge-
neticsusceptibilitymayalsoplayarole.In
our study, baseline plasma thiamine con-
centrations of 31.8  7.7 nmol/l in the
benfotiamine group and 31.6  9.8
nmol/l in the placebo group were higher
than the 16.3  11.5 nmol/l reported for
patients with type 2 diabetes in the U.K.,
but deﬁcient compared to the 64.1 
12.0 nmol/l reported for healthy control
subjects in that study (13).
Itisimportanttorealizethatthiamine
and benfotiamine are supposed to antag-
onize detrimental effects of hyperglyce-
mia (7). Yet, in two large intervention
studies, it took years of lowering A1C be-
fore a difference in UAE was found be-
tween strict metabolic control and
standard therapy (14,15). Our study may
therefore have been too short to demon-
strate the effect of benfotiamine.
In conclusion, longer-term interven-
tionstudiesand/orinterventionstudiesin
earlier stages of diabetic nephropathy are
necessary to discern whether benfo-
tiamine has an effect on the development
of diabetic nephropathy.
Acknowledgments— This trial was partly
fundedbyagrantfromtheEuropeanUnionto
PREDICTIONS (Prevention of Diabetes Com-
plication) network and by the medical re-
search foundation in Zwolle.
U.A. is the head of medical affairs in Wo ¨r-
wag Pharma Co., and contributed in the prep-
aration of the study protocol and other
necessary documents needed for approval of
the study by the ethics committee and author-
itiesbutwasnotdirectlyorindirectlyinvolved
in the practical procedures, inclusion and
evaluation of subjects, data collection, or data
analysis.
No potential conﬂicts of interest relevant to
this article were reported.
A.A. researched data and wrote the manu-
script. A.K., W.V.O., and R.J.S. researched
data. U.A. and G.S.M. contributed to the dis-
cussion. N.K., H.J.G.B., R.O.B.G., G.J.N., and
S.J.L.B. contributed to the discussion and re-
viewed/edited the manuscript.
The authors acknowledge the efforts of Drs.
J. Lambert and J.E. Heeg (Isala clinics, Zwolle,
the Netherlands) and Dr. J. Jager (Diacones-
senhuis Hospital, Meppel, the Netherlands) in
preparing the study. The authors thank Dr.
L.D. Dikkeschei, M. van der Saag, and M.
Slingschro ¨der (clinical chemical laboratories
in the Isala Clinics, Zwolle, the Netherlands)
and H. Breukelman (clinical chemical labora-
tories at the University Medical Center,
Groningen, the Netherlands) for their collab-
oration. The authors also acknowledge the ef-
forts of Dr. W. Gaus (University of Ulm,
Germany) as independent statistician.
References
1. Fioretto P, Bruseghin M, Berto I, Gallina
P, Manzato E, Mussap M. Renal protec-
tion in diabetes: role of glycemic control.
J Am Soc Nephrol 2006;17:S86–S89
2. Nath KA. Tubulointerstitial changes as a
major determinant in the progression of
renal damage. Am J Kidney Dis 1992;20:
1–17
3. Lewis EJ, Hunsicker LG, Clarke WR, Berl
T, Pohl MA, Lewis JB, Ritz E, Atkins RC,
Rohde R, Raz I, Collaborative Study
Group.Renoprotectiveeffectoftheangio-
tensin-receptor antagonist irbesartan in
patients with nephropathy due to type 2
diabetes. N Engl J Med 2001;345:851–
860
4. Bakker SJ, Heine RJ, Gans RO. Thiamine
may indirectly act as an antioxidant. Dia-
betologia 1997;40:741–742
5. Babaei-JadidiR,KarachaliasN,AhmedN,
Battah S, Thornalley PJ. Prevention of in-
cipient diabetic nephropathy by high-
dosethiamineandbenfotiamine.Diabetes
2003;52:2110–2120
6. Schreeb KH, Freudenthaler S, Vormfelde
SV, Gundert-Remy U, Gleiter CH. Com-
parative bioavailability of two vitamin B1
preparations: benfotiamine and thiamine
mononitrate. Eur J Clin Pharmacol 1997;
52:319–320
7. Hammes HP, Du X, Edelstein D, Taguchi
Benfotiamine treatment in diabetic nephropathy
1600 DIABETES CARE, VOLUME 33, NUMBER 7, JULY 2010 care.diabetesjournals.orgT, Matsumura T, Ju Q, Lin J, Bierhaus A,
Nawroth P, Hannak D, Neumaier M,
Bergfeld R, Giardino I, Brownlee M. Ben-
fotiamine blocks three major pathways of
hyperglycemic damage and prevents ex-
perimental diabetic retinopathy. Nat Med
2003;9:294–299
8. Schrijver J, Speek AJ, Klosse JA, van Rijn
HJ, Schreurs WH. A reliable semiauto-
mated method for the determination of
total thiamine in whole blood by the thio-
chrome method with high-performance
liquid chromatography. Ann Clin Bio-
chem 1982;19:52–56
9. Milner CR, Buttery JE, Chamberlain BR.
The measurement of erythrocyte transke-
tolase activity on a discrete analyser. J Au-
tomat Chem 1982;4:183–185
10. van Timmeren MM, Vaidya VS, van Ree
RM, Oterdoom LH, de Vries AP, Gans RO,
van Goor H, Stegeman CA, Bonventre JV,
BakkerSJ.Highurinaryexcretionofkidney
injury molecule-1 is an independent pre-
dictor of graft loss in renal transplant recip-
ients.Transplantation2007;84:1625–1630
11. Rabbani N, Alam SS, Riaz S, Larkin JR,
AkhtarMW,ShaﬁT,ThornalleyPJ.High-
dose thiamine therapy for patients with
type 2 diabetes and microalbuminuria: a
randomised, double-blind placebo-con-
trolled pilot study. Diabetologia 2009;52:
208–212
12. Rabbani N, Alam SS, Riaz S, Larkin JR,
Akhtar MW, Shaﬁ T, Thornalley PJ. Thi-
amine in diabetic nephropathy: a novel
treatment modality? Reply to Alkhalaf A,
Kleefstra N, Groenier KH et al. (Letter).
Diabetologia 2009;52:1214–1216
13. Thornalley PJ, Babaei-Jadidi R, Al Ali H,
RabbaniN,AntonysunilA,LarkinJ,Ahmed
A, Rayman G, Bodmer CW. High preva-
lenceoflowplasmathiamineconcentration
in diabetes linked to a marker of vascular
disease. Diabetologia 2007;50:2164–2170
14. Effect of intensive therapy on the devel-
opment and progression of diabetic ne-
phropathy in the Diabetes Control and
Complications Trial. The Diabetes Con-
trol and Complications (DCCT) Research
Group. Kidney Int 1995;47:1703–1720
15. Bilous R. Microvascular disease: what
does the UKPDS tell us about diabetic ne-
phropathy? Diabet Med 2008;25(Suppl.
2):25–29
Alkhalaf and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 7, JULY 2010 1601